The bets on liquid biopsy keep getting bigger. Last month, Silicon Valley unicorn Grail Inc. raised a third round of financing to develop its blood-based tests for early cancer detection. That brings its total up to $1.5 billion since 2016, putting it among the top three most heavily funded private biotech companies in the US. …
Continue reading “A Blood-Based Cancer Test Gets Its First Results”